[Association of single nucleotide polymorphisms of tissue factor and tissue factor pathway inhibitor with venous thromboembolism in patients with lung cancer].

s To investigate the distributions of single nucleotide polymorphisms (SNPs) of tissue factor (TF) and its inhibitor tissue factor pathway inhibitor (TFPI) and analyze the association of the SNPs with venous thromboembolism (VTE) in lung cancer patients. Between October 2009 and August 2013, a total of 152 hospitalized patients with newly diagnosed primary non-small cell lung cancer were enrolled from Beijing Chao Yang Hospital. Among them [male 105 cases, female 47 cases, with an age of (62.4±13.2) years old], 40 cases were lung cancer patients with VTE, 112 cases were lung cancer patients without VTE. In the same period, 79 healthy controls were included from the physical examination center. All patients' blood specimens were collected and their DNA was isolated. The selected SNPs were TF+ 5466A/G, TFPI-287T/C and TFPI-33T/C and they were investigated by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) followed by validation of DNA sequence analysis. Allelic frequencies of TF+ 5466G, TFPI-287C and TFPI-33C were 2.5%, 33.8% and 8.8%, respectively. There was no significant difference among the three groups in genotype or allele frequency distributions of TF+ 5466A/G, TFPI-287T/C and TFPI-33T/C polymorphisms (all >0.05). There was no difference from different genders and ages in allele or genotype frequency distributions of TF+ 5466A/G, TFPI-287T/C and TFPI-33T/C polymorphisms among the three groups (all >0.05). Meanwhile, the frequency distributions of genotype and allele of the three SNPs were not associated with lung cancer patients with VTE (all >0.05). Still, no relationship was found between genotype or allele frequency distributions of the three SNPs with prognosis of lung cancer patients with VTE. Genotype alterations in TF+ 5466A/G, TFPI-287T/C and TFPI-33T/C may be unrelated to the occurrence of VTE and the prognosis of lung cancer patients with VTE.